StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review

Reuters

Feb 11

StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review

StenoCare A/S has submitted a full regulatory dossier for its ASTRUM 10-10 oil product to French medical authorities as part of the national process to evaluate medical cannabis for potential reimbursement following France's 2021-2025 pilot programme. The submission was made in partnership with the Institut des Cannabinoïdes Médicaux Français (ICMF). The regulatory review by the Haute Autorité de Santé $(HAS)$ is a key step in determining whether and under what conditions medical cannabis treatments may be reimbursed in France. Movianto, a leading French pharmaceutical distributor, will handle nationwide logistics and pharmacy supply if approval is granted.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: BITN____20260210BIT9015) on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610985444"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610985444\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610985444?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 15:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610985444","market":"fut","top_or_hot":-1,"title":"StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        StenoCare A/S has submitted a full regulatory dossier for its ASTRUM 10-10 oil product to French medical authorities as part of the national process to evaluate medical cannabis for potential reimbursement following France's 2021-2025 pilot programme. The submission was made in partnership with the Institut des Cannabinoïdes Médicaux Français (ICMF). The regulatory review by the Haute Autorité de Santé <a href=\"https://laohu8.com/S/HAS\">$(HAS)$</a> is a key step in determining whether and under what conditions medical cannabis treatments may be reimbursed in France. Movianto, a leading French pharmaceutical distributor, will handle nationwide logistics and pharmacy supply if approval is granted.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: BITN____20260210BIT9015) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 15:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        StenoCare A/S has submitted a full regulatory dossier for its ASTRUM 10-10 oil product to French medical authorities as part of the national process to evaluate medical cannabis for potential reimbursement following France's 2021-2025 pilot programme. The submission was made in partnership with the Institut des Cannabinoïdes Médicaux Français (ICMF). The regulatory review by the Haute Autorité de Santé <a href=\"https://laohu8.com/S/HAS\">$(HAS)$</a> is a key step in determining whether and under what conditions medical cannabis treatments may be reimbursed in France. Movianto, a leading French pharmaceutical distributor, will handle nationwide logistics and pharmacy supply if approval is granted.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: BITN____20260210BIT9015) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1147","symbol_name":"投资银行业与经纪业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL5jphPx:1","article_id":"2610985444","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610985444","pubTimestamp":1770793417,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"StenoCare A/S has submitted a full regulatory dossier for its ASTRUM 10-10 oil product to French medical authorities as part of the national process to evaluate medical cannabis for potential reimbursement following France's 2021-2025 pilot programme. The submission was made in partnership with the Institut des Cannabinodes Médicaux Franais . The regulatory review by the Haute Autorité de Santé  is a key step in determining whether and under what conditions medical cannabis treatments may be reimbursed in France. Movianto, a leading French pharmaceutical distributor, will handle nationwide logistics and pharmacy supply if approval is granted.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1147":"投资银行业与经纪业","08333":"阿仕特朗金融"},"translate_title":"StenoCare提交医用大麻产品档案供法国监管审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08333":0.9},"content_text":"StenoCare Submits Medical Cannabis Product Dossier for French Regulatory Review\n    \n\n        StenoCare A/S has submitted a full regulatory dossier for its ASTRUM 10-10 oil product to French medical authorities as part of the national process to evaluate medical cannabis for potential reimbursement following France's 2021-2025 pilot programme. The submission was made in partnership with the Institut des Cannabinoïdes Médicaux Français (ICMF). The regulatory review by the Haute Autorité de Santé $(HAS)$ is a key step in determining whether and under what conditions medical cannabis treatments may be reimbursed in France. Movianto, a leading French pharmaceutical distributor, will handle nationwide logistics and pharmacy supply if approval is granted.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: BITN____20260210BIT9015) on February 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}